MAINTENANCE PHASE I: Patients with antibody titer < 1:4000 and who do not experience a DLT receive CIMAvax every 4 weeks and nivolumab every 2 weeks. Patients with antibody titer >= 1:4000 and who do not experience a DLT are randomized to 1 of 3 groups.